Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Midazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.52 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.52 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.52 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.52 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.52 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | PTAFR | P25105 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midazolam SCHEMBL1311204 | 1.00 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29419655 | 1.00 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29445200 | 1.00 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29565146 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL5783371 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29735381 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29480459 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL35061 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL29357425 | 0.99 | OPRK1 (1.00) | OPRK1CYP3A4PDE4DDRD3SLC22A1 | |
| Midazolam SCHEMBL15270674 | 0.98 | OPRK1 (0.98) | OPRK1CYP3A4PDE4DDRD3SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3752 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629380-B2 | Oral film unit dosage form | SWIPP AB (SE) | 2026-05-19 | — | — | US | claimed |
| EP-4687838-A2 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. Braun Melsungen AG (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4673122-A1 | ORAL FILM UNIT DOSAGE FORM | SWIPP AB (SE) | 2026-01-07 | — | — | EP | claimed |
| EP-4673121-A1 | CRYSTALLINE FORM OF MIDAZOLAM HYDROCHLORIDE | SWIPP AB (SE) | 2026-01-07 | — | — | EP | claimed |
| CN-116041351-B | Novel midazolam hydrochloride crystal form and preparation method thereof | 成都硕德药业有限公司 | 2025-06-03 | — | — | CN | claimed |
| US-20240374611-A1 | ORAL FILM UNIT DOSAGE FORM | SWIPP AB (SE) | 2024-11-14 | — | — | US | claimed |
| WO-2024209420-A2 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. BRAUN MELSUNGEN AG (DE) | 2024-10-10 | — | — | WO | claimed |
| EP-4442249-A1 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. Braun Melsungen AG (DE) | 2024-10-09 | — | — | EP | claimed |
| WO-2024180209-A1 | CRYSTALLINE FORM OF MIDAZOLAM HYDROCHLORIDE | SWIPP AB (SE) | 2024-09-06 | — | — | WO | claimed |
| WO-2024180208-A1 | ORAL FILM UNIT DOSAGE FORM | SWIPP AB (SE) | 2024-09-06 | — | — | WO | claimed |
| US-20040191898-A1 | Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-09-30 | — | — | US | claimed |
| CN-1501795-A | Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye | ��������²�ʿ��ѧҩ������ɷ����� | 2004-06-02 | — | — | CN | claimed |
| US-20030198664-A1 | Lipid mediated screening of drug candidates for identification of active compounds | FLORIDA, UNIVERSITY OF | 2003-10-23 | — | — | US | claimed |
| WO-2003083443-A2 | LIPID MEDIATED SCREENING OF DRUG CANDIDATES FOR IDENTIFICATION OF ACTIVE COMPOUNDS | UNIVERSITY OF FLORIDA (US) | 2003-10-09 | — | — | WO | claimed |
| US-20030147812-A1 | Device and methods for initiating chemical reactions and for the targeted delivery of drugs or other agents | DORNIER MEDTECH SYSTEMS GMBH. (DE) | 2003-08-07 | — | — | US | claimed |
| US-20020124272-A1 | PROTEIN KINASE C EPSILON AS MODULATOR OF ANXIETY, ALCOHOL CONSUMPTION AND SELF-ADMINISTRATION OF DRUGS OF ABUSE | ERNEST GALLO CLINIC AND RESEARCH CENTER | 2002-09-05 | — | — | US | claimed |
| EP-1095136-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | Messing, Robert O. (US) | 2001-05-02 | — | — | EP | claimed |
| US-6114370-A | Amnesic sedation composition and method of administering same | W. H. WALL FAMILY HOLDINGS, LLLP | 2000-09-05 | — | — | US | claimed |
| WO-2000001805-A1 | CELLS AND ANIMALS DEFICIENT IN PROTEIN KINASE C EPSILON | MESSING ROBERT O (US) | 2000-01-13 | — | — | WO | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |